2024
Quadrivalent Conjugate Vaccine and Invasive Meningococcal Disease in US Adolescents and Young Adults
Shin T, Wells C, Shoukat A, Potter-Schwartz L, Langevin E, Langley J, Galvani A, Moghadas S. Quadrivalent Conjugate Vaccine and Invasive Meningococcal Disease in US Adolescents and Young Adults. JAMA Network Open 2024, 7: e2443551. PMID: 39504021, PMCID: PMC11541638, DOI: 10.1001/jamanetworkopen.2024.43551.Peer-Reviewed Original ResearchConceptsInvasive meningococcal diseaseInvasive meningococcal disease casesCases of invasive meningococcal diseaseQuadrivalent conjugate vaccineUS adolescentsMeningococcal diseaseConjugate vaccineMenACWY vaccineIncidence rates of invasive meningococcal diseasePrevention of invasive meningococcal diseaseIncidence rateBurden of meningococcal diseaseUS adolescent populationUS populationYoung adultsImmunization of adolescentsIncidence of invasive meningococcal diseaseBayesian hierarchical Poisson regression modelsDecision analytical studyRate of invasive meningococcal diseaseMenACWY vaccination programUnvaccinated individualsDecision analytic modelHierarchical Poisson regression modelYears of ageEstimating the lives that could be saved by expanded access to weight-loss drugs
Pandey A, Ye Y, Wells C, Singer B, Galvani A. Estimating the lives that could be saved by expanded access to weight-loss drugs. Proceedings Of The National Academy Of Sciences Of The United States Of America 2024, 121: e2412872121. PMID: 39405358, PMCID: PMC11513960, DOI: 10.1073/pnas.2412872121.Peer-Reviewed Original ResearchConceptsGlucagon-like peptide-1Body mass index categoriesObesity prevalence dataGlucagon-like peptide-1 receptor agonistsHazard ratio of mortalityRatio of mortalityPublic health impactWeight loss drugsInsurance coverage issuesGastric inhibitory polypeptideHealthcare accessType 2 diabetesUnited StatesPublic health crisisObesity epidemicReceptor agonistsIndex categoriesHazard ratioPrevalence dataInhibitory polypeptidePeptide-1Health impactsNovel treatmentObesityHealth crisisMortality and morbidity ramifications of proposed retractions in healthcare coverage for the United States
Pandey A, Fitzpatrick M, Singer B, Galvani A. Mortality and morbidity ramifications of proposed retractions in healthcare coverage for the United States. Proceedings Of The National Academy Of Sciences Of The United States Of America 2024, 121: e2321494121. PMID: 38648491, PMCID: PMC11066981, DOI: 10.1073/pnas.2321494121.Peer-Reviewed Original ResearchA retrospective cohort study of Paxlovid efficacy depending on treatment time in hospitalized COVID-19 patients
Du Z, Wang L, Bai Y, Liu Y, Lau E, Galvani A, Krug R, Cowling B, Meyers L. A retrospective cohort study of Paxlovid efficacy depending on treatment time in hospitalized COVID-19 patients. ELife 2024, 13: e89801. PMID: 38622989, PMCID: PMC11078542, DOI: 10.7554/elife.89801.Peer-Reviewed Original ResearchConceptsViral sheddingHospitalized COVID-19 patientsSARS-CoV-2Retrospective cohort studyRisk of reboundCOVID-19 patientsViral reboundTime of treatmentTreated patientsPreventing severe illnessEarly treatmentCohort studyHospitalized patientsPatientsViral replicationReducing infectiousnessSevere illnessTimely treatmentViral dynamicsHealth record dataTreatmentTransmission riskTransmission of SARS-CoV-2EfficacySymptoms
2015
The Impact of Enhanced Screening and Treatment on Hepatitis C in the United States
Durham DP, Skrip LA, Bruce RD, Vilarinho S, Elbasha EH, Galvani AP, Townsend JP. The Impact of Enhanced Screening and Treatment on Hepatitis C in the United States. Clinical Infectious Diseases 2015, 62: 298-304. PMID: 26628566, PMCID: PMC4706637, DOI: 10.1093/cid/civ894.Peer-Reviewed Original ResearchConceptsHepatitis C virusInterferon-free DAAsHCV incidenceTreatment ratesChronic hepatitis C virusCases of cirrhosisInjection drug useImpact of administrationAnnual treatment ratesEnhanced screeningHCV prevalenceHCV screeningDecompensated cirrhosisHCV infectionHCV transmissionHepatitis CLiver transplantActing antiviralsLevels of screeningPatients 4C virusHepatocellular carcinomaEpidemiological dataUniversal screeningDrug use
2013
Cost-effectiveness of a community-based intervention for reducing the transmission of Schistosoma haematobium and HIV in Africa
Mbah M, Kjetland EF, Atkins KE, Poolman EM, Orenstein EW, Meyers LA, Townsend JP, Galvani AP. Cost-effectiveness of a community-based intervention for reducing the transmission of Schistosoma haematobium and HIV in Africa. Proceedings Of The National Academy Of Sciences Of The United States Of America 2013, 110: 7952-7957. PMID: 23589884, PMCID: PMC3651507, DOI: 10.1073/pnas.1221396110.Peer-Reviewed Original ResearchConceptsCommunity-based interventionsHIV infectionHIV transmissionSchistosoma haematobiumFemale genital schistosomiasisAdministration of praziquantelSaharan AfricaRural ZimbabweS. haematobium transmissionGenital schistosomiasisGenital infectionHealth payersSchool-aged childrenIntervention periodEpidemiological dataEpidemiological studiesS. haematobiumSchistosomiasis prevalenceHealth educationInfectionSchistosomiasisYoung womenHaematobiumInterventionHIV
2012
Using Game Theory to Examine Incentives in Influenza Vaccination Behavior
Chapman GB, Li M, Vietri J, Ibuka Y, Thomas D, Yoon H, Galvani AP. Using Game Theory to Examine Incentives in Influenza Vaccination Behavior. Psychological Science 2012, 23: 1008-1015. PMID: 22810166, DOI: 10.1177/0956797612437606.Peer-Reviewed Original Research
2010
Adherence to cervical screening in the era of human papillomavirus vaccination: how low is too low?
Bauch CT, Li M, Chapman G, Galvani AP. Adherence to cervical screening in the era of human papillomavirus vaccination: how low is too low? The Lancet Infectious Diseases 2010, 10: 133-137. PMID: 20113982, DOI: 10.1016/s1473-3099(10)70004-9.Peer-Reviewed Original ResearchConceptsCervical cancerVaccinated womenVaccine coverageEffective cervical screening programmesHuman papillomavirus vaccinationCervical screening programmeHigh-risk typesIntroduction of vaccinesPapillomavirus vaccinationOncogenic typesCervical screeningOpportunistic screeningScreening programPrevents infectionCancerVaccineIncidenceContinued screeningWomenVaccinationScreeningPopulationDisease incidenceInfection
2008
Integrating epidemiology, psychology, and economics to achieve HPV vaccination targets
Basu S, Chapman GB, Galvani AP. Integrating epidemiology, psychology, and economics to achieve HPV vaccination targets. Proceedings Of The National Academy Of Sciences Of The United States Of America 2008, 105: 19018-19023. PMID: 19015536, PMCID: PMC2596236, DOI: 10.1073/pnas.0808114105.Peer-Reviewed Original ResearchConceptsHPV vaccinationCervical cancerVaccination levelsVaccination targetsCervical cancer prevention programsHuman papillomavirus vaccineVaccine-eligible childrenCancer prevention programsHealth-related utilityVaccine recipientsGenital wartsPapillomavirus vaccineVaccination recommendationsVaccination goalsVaccine risksPrevention programsVaccinationSexual activityCancerCoverage planCost subsidizationSurvey respondentsVaccineEpidemiologyIncidence
2005
Dimensions of superspreading
Galvani AP, May RM. Dimensions of superspreading. Nature 2005, 438: 293-295. PMID: 16292292, PMCID: PMC7095140, DOI: 10.1038/438293a.Peer-Reviewed Original Research